Page 17 - TROMBOCITOPENIA INMUNE PRIMARIA (PTI)
P. 17
Bibliografía recomendada
Discontinuación de los AR-TPO
González-López TJ, Pascual C, Álvarez-Román MT, Fernández-Fuertes F, Sánchez- González B, Caparrós I, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015 Mar;90(3):E40-3. [Pubmed]
Newland A, Godeau B, Priego V, Viallard JF, López Fernández MF, Orejudos A, Eisen M.
Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016 Jan. [Pubmed]
PTI y COVID-19
ASH. COVID-19 and ITP: frequently asked Questions. Available at: [Enlace]
Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, Laffan M, et al. Practical guidance for the management of adults with immune tromboytopenia during the COVID-19 pandemic. Br J Haematol. 2010;189(6):1038-43. [Pubmed]
SEHH. Recomendaciones para el manejo de los enfermos con trombocitopenia inmune en la situación actual de pandemia por COVID-19. Avaible at: [Enlace]
